From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can ...

A crash course on the bubble itself, including therapeutic areas most affected. This column marks the first of a six-part series on “Popping the Gross-to-Net (GTN) Bubble" in the pharmaceutical ...

Embedding access tools at prescribing reduces manual enrollment, portal switching, and late activation, enabling faster ...

Shawn Seamans, Chief Commercial Officer, CoverMyMeds | Authors | Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking ...

Lilly will pay $6.75 per share (~26% premium), totaling $2.8 billion upfront with up to $1 billion milestone-based consideration, and expects closure in Q3 2026. Federal acceleration of psychedelic ...

Brent Wilhelm of Cencora discusses why available inventory still leads to shortages, and how tighter distributor-manufacturer integration and AI could close the gap. In part 1 of a 3-part interview ...

In this Dedicated Dialogue episode, Adam Fox, Chief Quality & Regulatory Affairs Officer of Cryoport Systems, explores how escalating regulatory expectations and patient-centric risk considerations ...

Episode 1 of Supply Chain Signal breaks down the FDA's PreCheck pilot, the US Section 301 probe into German drug pricing, and CMS's move to make Medicare drug price negotiation permanent. The debut ...

PwC's Roel van den Akker says pharma M&A ran beyond expectations in the first half of 2026, with dealmaking potentially on pace to hit $300 billion in H2. Pharmaceutical Commerce recently checked in ...

Beijing’s regulations effectively penalize compliance with US/EU/UK sanctions, export controls, and forced-labor regimes, converting routine supplier-management actions into potential retaliatory ...